High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership

Autor: Carlucci, Philip M, Li, Jessica, Fava, Andrea, Deonaraine, Kristina K, Wofsy, David, James, Judith A, Putterman, Chaim, Diamond, Betty, Davidson, Anne, Fine, Derek M, Monroy-Trujillo, Jose, Atta, Mohamed G, DeJager, Wade, Guthridge, Joel M, Haag, Kristin, Rao, Deepak A, Brenner, Michael B, Lederer, James A, Apruzzese, William, Belmont, H Michael, Izmirly, Peter M, Zaminski, Devyn, Wu, Ming, Connery, Sean, Payan-Schober, Fernanda, Furie, Richard, Dall'Era, Maria, Cho, Kerry, Kamen, Diane, Kalunian, Kenneth, Anolik, Jennifer, Barnas, Jennifer, Ishimori, Mariko, Weisman, Michael H, Accelerating Medicines Partnership (AMP) RA/SLE Network, Buyon, Jill P, Petri, Michelle
Rok vydání: 2022
Předmět:
Zdroj: Rheumatology (Oxford, England), vol 61, iss 11
Popis: ObjectiveDelayed detection of LN associates with worse outcomes. There are conflicting recommendations regarding a threshold level of proteinuria at which biopsy will likely yield actionable management. This study addressed the association of urine protein:creatinine ratios (UPCR) with clinical characteristics and investigated the incidence of proliferative and membranous histology in patients with a UPCR between 0.5 and 1.MethodsA total of 275 SLE patients (113 first biopsy, 162 repeat) were enrolled in the multicentre multi-ethnic/racial Accelerating Medicines Partnership across 15 US sites at the time of a clinically indicated renal biopsy. Patients were followed for 1 year.ResultsAt biopsy, 54 patients had UPCR
Databáze: OpenAIRE